---
document_datetime: 2025-09-11 10:53:45
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/loqtorzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: loqtorzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.2866643
conversion_datetime: 2025-12-15 00:58:38.169241
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## LOQTORZI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber    | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.b.2.cReplacementor additionofa | 10/09/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000293928                                       | manufacturerresponsibleforimportation and/or batch release - B.11.b.2.c.1 Not includingbatch control/testing-Accepted                          |            |            | PL                     |             |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------|
| Marketing Authorisation Transfer - H / EMA/T/0000254154 | -Transfer of a marketing authorisation- transfer ofmarketing authorisationfrom TMC Pharma (EU) Limited to Topalliance BiosciencesEuropeLimited | 12/03/2025 | 28/03/2025 | SmPC, Labelling and PL |             |
| PSUR/EMA/PSUR/0000257891                                |                                                                                                                                                |            |            |                        | Maintenance |